Trial Profile
Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Mar 2022 Status changed from recruiting to completed.
- 15 Sep 2014 New trial record